The content on this site is intended for healthcare professionals only
For the latest
cancer COVID-19 resources, click on this link
Prostate & urology
Lung & pleura
Colorectal & gastro
Melanoma & skin
Head & neck
Ovary & gynaecology
Brain & nervous system
cancer and the City Cancer Challenge have formed an educational collaboration. Learners who are part of the City Cancer Challenge's project can access additional education provided by them.
Please login or register. Then you can use this button to confirm you are part of this project.
Register for free
Already have an account?
Significance of gut microbiota in patients receiving CAR T cell immunotherapy
Prof Marco Ruella - University of Pennsylvania, Philadelphia, USA
17 Dec 2021
Exceptional response to oral metronomic chemotherapy in a rare case of sinonasal...
Dr Akhil Kapoor - Tata Memorial Hospital, Mumbai, India
21 Sep 2021
KEYNOTE-716: Adjuvant pembrolizumab prolongs recurrence-free survival in resecte...
Dr Jason Luke - UPMC Hillman Cancer Center, Pittsburgh, USA
18 Sep 2021
ESMO President: What to watch for at ESMO 2021
Prof Solange Peters - ESMO President
17 Sep 2021
Vaccinations in myeloma patients including for COVID-19
Prof Heinz Ludwig - Wilhelminen Cancer Research Institute, Vienna, Austria
31 Aug 2021
PrE0807: Neoadjuvant nivolumab without or with lirilumab in cisplatin-ineligible...
Dr Petros Grivas - Seattle Cancer Care Alliance, Seattle, USA
22 Jun 2021
CheckMate067 outcomes: Nivolumab plus ipilimumab in advanced melanoma
Dr Jedd Wolchok - Memorial Sloan Kettering Center, New York, USA
9 Jun 2021
LEAP-004: Lenvatinib + pembrolizumab for patients with advanced melanoma and con...
Dr Ana Arance - Hospital Clínic de Barcelona, Barcelona, Spain
8 Jun 2021
Highlights from ASCO 2021
Dr Bishal Gyawali - Queen's University, Kingston, Canada
8 Jun 2021
OncoAlert and ecancer ASCO roundup - Day 3
Dr Gil Morgan - Skåne University Hospital in Lund, Sweden
8 Jun 2021
RELATIVITY-047: Relatlimab (RELA) plus nivolumab (NIVO) versus NIVO in first-lin...
Dr Evan Jacob Lipson - Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, ...
4 Jun 2021
Phase III randomised trial comparing tebentafusp with investigator’s choice in f...
Dr Jessica Hassel - University Hospital Heidelberg, Heidelberg, Germany
16 Apr 2021